Envveno MedicalNVNO
13F holders, Q2 2026 (June 30)17holders
2new positions
3sold out
$10.75avg. 13F price*
At the end of Q2 2026, 17 institutions reported holding Envveno Medical Corp. (NVNO) in their 13F filings, unchanged from Q1 2026. 2 opened new positions and 3 sold out. The largest holders were Kingdon Capital Management, L.L.C. ($387K), CM Management, LLC ($382K) and Vanguard Capital Management LLC ($67K).
- Company
- Envveno Medical Corp.
- CUSIP
- 29415J205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $6K |
| Exits | 3 | $106K |
All 13F filers, Q1 2026 → Q2 2026: 541 shares bought and 12,419 shares sold, net −11,878 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Kingdon Capital Management, L.L.C. | 0.05% | No change | 36,166 | $387K |
| CM Management, LLC | 0.24% | No change | 35,714 | $382K |
| Vanguard Capital Management LLC | 0.00% | No change | 6,287 | $67K |
| JPMorgan Chase & Co. | 0.00% | Reduce -0.0% | 5,208 | $59K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 2,184 | $23K |
| Westside Investment Management, Inc. | 0.00% | Reduce -4.0% | 1,525 | $16K |
| Mirae Asset Global Investments Co., Ltd. | 0.00% | New | 539 | $6K |
| BlackRock, Inc. | 0.00% | Reduce -77.5% | 414 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -38.9% | 331 | $4K |
| Wells Fargo & Company | 0.00% | No change | 114 | $1K |
| Allied Private Wealth LLC | 0.00% | — | 88 | $978 |
| Vanguard Global Advisers, LLC | 0.00% | No change | 77 | $825 |
| Morgan Stanley | 0.00% | Reduce -22.4% | 59 | $632 |
| Osaic Holdings, Inc. | 0.00% | No change | 7 | $74 |
| Barclays PLC | 0.00% | New | 2 | $21 |
| Group One Trading LLC | 0.00% | No change | 2 | $21 |
| UBS Group AG | 0.00% | Reduce -99.6% | 1 | $11 |
"% of holder's portfolio" is NVNO's weight in each manager's 13F, not the share of Envveno Medical Corp. the manager owns.